Anti-B7-2 monoclonal antibody GL-1

Drug Profile

Anti-B7-2 monoclonal antibody GL-1

Alternative Names: Anti-CD86 monoclonal antibody GL-1; GL-1

Latest Information Update: 11 Nov 2003

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Repligen
  • Developer Repligen; Roche
  • Class Antihyperglycaemics; Monoclonal antibodies
  • Mechanism of Action CD86 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Transplant rejection; Type 1 diabetes mellitus

Most Recent Events

  • 11 Nov 2003 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
  • 11 Nov 2003 Discontinued - Preclinical for Type-1 diabetes mellitus in USA (unspecified route)
  • 10 Aug 1998 No-Development-Reported for Transplant rejection in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top